Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

St. Petersburg Times Examines Work Of Paul Farmer, Potential Candidate For USAID, State Department Position
The St. Petersburg Times examines the work of Paul Farmer - "the Harvard-educated doctor who, starting in Haiti, built a multinational organization on the radical idea that poor patients deserve the same care as rich ones" and is reportedly being considered for a high-level job with USAID or the State Department. The newspaper reports that though it"s "not a sure thing, even his candidacy indicates how far the international aid establishment has come around to Farmer"s way of thinking, health care experts say."
generic viagra online
Mouse Study Shows PET Can Measure Effectiveness Of Novel Breast Cancer Treatment
A new study published in the July issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended. Researchers successfully used PET and a specially-developed radioactive compound to image HER2 - a protein often associated with aggressive breast cancer - in breast cancer cells before and after treatment aimed at decreasing HER2 expression. This molecular imaging methodology could facilitate development of new targeted therapies not only for breast cancer, but also for certain types of ovarian, prostate, and lung cancers that may be aggravated due to HER2.
News of the day
Automated Tissue Engineering On Demand
Skin from a factory - this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of "skin models", which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.
Diagnostics

Merck Seeks European License For Cladribine for relapsing remitting MS

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington. If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS. Multiple Scleroris Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009